UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

Zantac Litigation is Born “The best starting point involves a private company known as Valisure. Valisure theorized that ranitidine [aka Zantac] has the potential to degrade into a carcinogen known as ...

Also Read | ‘Your behaviour not unnoticed,’ Philippines embarrasses China at ASEAN summit The over-the-counter treatment, known also by its non-commercial name ranitidine, was manufactured by ...

It follows concern in several countries over the presence of impurities in Zantac and other ranitidine products. Canada and France have already announced Zantac recalls. The US and the European ...

Glaxo’s patent for Zantac’s active ingredient, ranitidine, expired in 1997. That same year, pharmaceutical companies began ...